Belite BioBLTE

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Ratings

0 / 5

0 ratings in the last 12 months

5
4
3
2
1
CEO
Dr. Yu-Hsin Lin

$1.4B

Market Cap • 23/05/2024

2018

(há 6 anos)
Fundação

2022

(2 years ago)
IPO

NASDAQ

Listagem
Flag of US

San Diego

Sede • California

16

N° de Empregados • 2022

Valuation

Valuation Indicators

Retorno Histórico

BLTESó no Premium...

Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.

1%

1 dia

20/05/2024

8%

1 semana

16/05/2024

23%

1 mês

23/04/2024

92%

1 ano

23/05/2023

10 anos

Histórico